Author Archives: admin


"Self-eating" Process of Stem Cells May be Key to New Regenerative Therapies – Mirage News

Translucently colored embryonic stem (ES) cell (upper right) and its differentiating derivatives (left and lower right). The small round bodies inside cells represent lysosomes, with the pink color indicating ones that are undergoing chaperone-mediated autophagy (CMA), a selective form of autophagy that is demonstrated only in mammals. CMA governs the balance between self-renewal and differentiation of ES cells. It is kept at low levels in undifferentiated ES cells to maintain the pluripotent state. Upon induction of differentiation, CMA flux increases due to the reduction of pluripotency factors, leading to changes in cellular metabolism and epigenetic landscape that favor differentiation.

PHILADELPHIAThe self-eating process in embryonic stem cells known as chaperone-mediated autophagy (CMA) and a related metabolite may serve as promising new therapeutic targets to repair or regenerate damaged cells and organs, Penn Medicine researchers show in a new study published online in Science.

Human bodies contain over 200 different types of specialized cells. All of them can be derived from embryonic stem (ES) cells, which relentlessly self-renew while retaining the ability to differentiate into any cell type in adult animals, a state known as pluripotency. Researchers have known that the cells metabolism plays a role in this process; however, it wasnt clear exactly how the cells internal wiring works to keep that state and ultimately decide stem cell fate.

The new preclinical study, for the first time, shows how the stem cells keeps CMA at low levels to promote that self-renewal, and when the stem cell is ready, it switches that suppression off to enhance CMA, among other activities, and differentiate into specialized cells.

Its an intriguing discovery in the field of stem cell biology and for researchers looking to develop therapies for tissue or organ regeneration, said senior author Xiaolu Yang, PhD, a professor of Cancer Biology at the Abramson Family Cancer Research Institute in the Perelman School of Medicine at the University of Pennsylvania. We reveal two novel ways to potentially manipulate the self-renewal and differentiation of stem cells: CMA and a metabolite, known as alpha-ketoglutarate, that is regulated by CMA. Rationally intervening or guiding these functions could be a powerful way to increase the efficiency of regenerative medicine approaches.

Autophagy is a cell-eating mechanism necessary for survival and function of most living organisms. When cells self-eat, the intracellular materials are delivered to lysosomes, which are organelles that help break down these materials. There are a few forms of autophagy. However, unlike the other forms, which are present in all eukaryotic cells, CMA is unique to mammals. To date, the physiological role of CMA remains unclear.

Using metabolomic and genetic laboratory techniques on the embryonic stem cells of mice, the researchers sought to better understand significant changes that took place during their pluripotent state and subsequent differentiation.

They found that CMA activity is kept at a minimum due to two cellular factors critical for pluripotencyOct4 and Sox2that suppresses a gene known as LAMP2A, which provides instructions for making a protein called lysosomal associated membrane protein-2 necessary in CMA. The minimal CMA activity allows stem cells to maintain high levels of alpha-ketoglutarate, a metabolite that is crucial to reinforce a cells pluripotent state, the researchers found.

When its time for differentiation, the cells begin to upregulate CMA due to the reduction in Oct4 and Sox2. Augmented CMA activity leads to the degradation of key enzymes responsible for the production of alpha-ketoglutarate. This leads to a reduction in alpha-ketoglutarate levels as well as an increases in other cellular activities to promote differentiation. These findings reveal that CMA and alpha-ketoglutarate dictate the fate of embryonic stem cells.

Embryonic stem cells are often called pluripotent due to their remarkable ability to give rise to every cell type in the body, except the placenta and umbilical cord. Embryonic stem cells not only provide a superb system to study early mammalian development, but also hold great promise for regenerative therapies to treat various human disorders. The development of stem-cell based regenerative medicine therapies has rapidly increased in the last decade, with several approaches in studies shown to repair damaged heart tissue, replace cells in solid organ transplantation, and in some cases address neurological disorders.

This newly discovered role of autophagy in the stem cell is the beginning of further investigations that could lead to researchers and physician-scientists to better therapies to treat various disorders, Yang said.

Penn co-authors of the study include the first author Yi Xu, a post-doctoral researcher in Yangs Lab, Yang Zhang and Sixiang Yu, also in Yangs lab, Lili Guo and Ian A. Blair of the department of Systems Pharmacology and Translational Therapeutics, Mengyuan Kan of the department of Biostatistics, Epidemiology and Informatics, as well as Juan C. Garca-Caaveras and Joshua D. Rabinowitz of Princeton University.

The study was supported the National Institutes of Health (R01CA182675, R01CA184867, R01CA235760, and P30ES013508, and the Department of Defense (W81XWH-15-1-0678).

View post:
"Self-eating" Process of Stem Cells May be Key to New Regenerative Therapies - Mirage News

R3 International Offering New Program for Stem Cell Therapy for Back Pain in Mexico – Yahoo Finance

The leading stem cell treatment center in Mexico, R3 International, is now offering a new program for stem cell therapy for back pain. The treatments include 30 million stem cells up to 200 million, and start at only $2975.

SCOTTSDALE, Ariz., July 27, 2020 /PRNewswire-PRWeb/ -- The leading stem cell treatment center in Mexico, R3 International, is now offering a new program for stem cell therapy for back pain. The treatments include 30 million stem cells up to 200 million, and start at only $2975.

With close to 9 out of 10 experiencing significant back pain at some point in life, there are millions of individuals who deal with back pain every day. It may be incapacitating, with traditional treatment options often not working exceptionally well. This may include risky narcotics or surgery.

According to R3 CEO David Greene, MD, MBA, "Chronic back pain dampens quality of life, with patients often not being able to work or play with their kids or grandkids. Stem cell treatment with R3 in Mexico is a fantastically effective option for those who want to eliminate pain without surgery or narcotics. It starts at only $2975 too!"

Stem cell therapy for back pain in Mexico at R3 International provides a safe, effective option for patients to alleviate back pain without surgery. Depending on the patient's reason for back pain, treatment may be provided IV, injection, intrathecal or with a combination. Each individual undergoes a free consultation with one of R3's licensed, experienced stem cell doctors who will review medical records and make the treatment suggestion.

Patient satisfaction at R3 Stem Cell International exceeds 87% overall, with treatments being offered for back pain, joint arthritis, Lyme disease, kidney failure, COPD, stroke, neuropathy, Alzheimers, diabetes, Crohns and more. Patients receive an escort from San Diego to the Tijuana clinic, which is only 20 minutes away along with an escort to the treatment and back.

To get set up for a free phone consultation, call (888) 988-0515 and visit https://stemcelltreatmentclinic.com for more information.

SOURCE R3 Stem Cell International

Read the original:
R3 International Offering New Program for Stem Cell Therapy for Back Pain in Mexico - Yahoo Finance

Autologous Stem Cell and Non-Stem Cell Based Therapies Market To Grow at a Stayed CAGR from 2019 to 2026 – Owned

Data Bridge Market research has published yet another new report thoroughly explains each and every aspect related to the Autologous Stem Cell and Non-Stem Cell Based Therapies market. This report can help the user to better understand the opportunities and threats that are doled by the industry and its players. The different areas covered in the report are Global Autologous Stem Cell and Non-Stem Cell Based Therapies market size, drivers and restraints, segment analysis, geographic outlook, major manufacturers in the market, competitive landscape, value/volume data, marketing strategies, and expert views.

Get Free Full PDF Sample Copy of Report + Full TOC, List of Tables, Figures & Chart at: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market research report assembles data collected from different regulatory organizations to assess the growth of the segments. In addition, the study also appraises the global Autologous Stem Cell and Non-Stem Cell Based Therapies market on the basis of topography. It reviews the macro- and microeconomic features influencing the growth of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market in each region. Various methodological tools are used to analyze the growth of the worldwide Autologous Stem Cell and Non-Stem Cell Based Therapies market.

List of Companies Profiled in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report are:

Takeda Pharmaceutical Company Limited, Cytori Therapeutics Inc., General Electric Spiegelberg GmbH & Co. KG ., Medtronic, Natus Medical Incorporated., Integra LifeSciences Corporation, RAUMEDIC AG, Abbott., Endotronix, Inc. among others.

Major Regions as Follows:

North America

Europe

Asia-Pacific

South America

Middle East and Africa

Key Answers Captured in Autologous Stem Cell and Non-Stem Cell Based Therapies Objectives are:

Key Important Pointers Covered in the Autologous Stem Cell and Non-Stem Cell Based Therapies Market Industry Trendsand Forecast to 2026

A complete value chain of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market is presented in the research report. It is associated with the review of the downstream and upstream components of the Autologous Stem Cell and Non-Stem Cell Based Therapies Market. The market is spliton the basis of the categories of products and clientapplication segments. The market analysis demonstrates the expansion of each segment of the global Autologous Stem Cell and Non-Stem Cell Based Therapies market. The research report assists the user in taking a decisive step on the way tobe a milestone ingrowingandexpandingtheirorganizationsinside theworldwideAutologous Stem Cell and Non-Stem Cell Based Therapies market.

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart):https://www.databridgemarketresearch.com/toc/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

The report highlights current and future market trends and carries out an analysis of the effect of buyers, substitutes, new entrants, competitors, and suppliers on the market. The key topics that have been explained in this Autologous Stem Cell and Non-Stem Cell Based Therapies market report include market definition, market segmentation, key developments, competitive analysis and research methodology.

The key highlights of this report

TABLE OF CONTENTS

Part 01:Executive Summary

Part 02:Scope of the Report

Part 03:Research Methodology

Part 04:Market Landscape

Part 05:Pipeline Analysis

Part 06:Market Sizing

Market Definition

Market Sizing

Market Size And Forecast

Part 07:Five Forces Analysis

Bargaining Power Of Buyers

Bargaining Power Of Suppliers

Threat Of New Entrants

Threat Of Substitutes

Threat Of Rivalry

Market Condition

Part 08:Market Segmentation

Segmentation

Comparison

Market Opportunity

Part 09:Customer Landscape

Part 10:Regional Landscape

Part 11:Decision Framework

Part 12:Drivers and Challenges

Part 13:Market Trends

Part 14:Vendor Landscape

Part 15:Vendor Analysis

Vendors Covered

Vendor Classification

Market Positioning Of Vendors

Part 16:Appendix

In conclusion, the Autologous Stem Cell and Non-Stem Cell Based Therapies Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report Give information such as economic scenarios, benefits, limits, trends, market growth rates, and figures. SWOT analysis is also incorporated in the report along with speculation attainability inspection and venture return investigation.

To Get the Short-Term and Long-Term Impact of COVID-19 on this Market:https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=europe-autologous-stem-cell-and-non-stem-cell-based-therapies-market

Thank you for reading this article. You can also get chapter-wise sections or region-wise report coverage for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Customization of the Report:

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

See the original post here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market To Grow at a Stayed CAGR from 2019 to 2026 - Owned

Cell Therapy Instrument Market IN COVID-19: IMPLICATIONS AND BUSINESS OPPORTUNITIES FOR GROWTH GLOBALLY – Owned

The Cell Therapy Instrument Market report has been recently added by Report Ocean to its vast repository. This intelligence report includes investigations based on Historical records, Current scenarios, and future predictions. It presents the 360-degree overview of the competitive landscape of the industries. SWOT analysis has been used to understand the Strength, Weaknesses, Opportunities, and threats in front of the businesses. Cell Therapy Instrument Market is showing steady growth and CAGR is expected to improve during the forecast period.

The Cell Therapy Instrument Market Research Report categorizes the Cell Therapy Instrument Market by key players, product type, applications, and regions, etc. The report also covers the latest industry data, key players analysis, market share, growth rate, opportunities and trends, investment strategy for your reference in analyzing the Cell Therapy Instrument Market.

COVID- 19 Impact on Cell Therapy Instrument Market

As companies move from reacting to mitigating the impact of the COVID-19 outbreak, they are keenly focusing on strategies that may result in emerging as strong market player. This market research report included the detailed study related to impact of COVID-19 on the supply chain based on both downstream and upstream markets. The report also includes the future development in the Cell Therapy Instrument Market in relation with the impact of COVID-19 on the market.

Request Free Sample Report athttps://www.reportocean.com/industry-verticals/sample-request?report_id=bis64080

Competitive Landscape:

This section of the report has mainly focused on Key Strategies adopted by leading players in Cell Therapy Instrument Market. These companies are selected based on revenue, innovations, strength of product portfolio, regional presence, investment capacity and similar other factors.

BD Bioscience Danaher (Beckman Coulter, Inc.) General Electric Lonza Merck Kgaa Miltenyi Biotec Sartorius AG Stemcell Technologies Inc. Terumo Corporation Thermo Fisher Scientific Inc.

Market Segmentation:

The segmentation is used to decide the target market into smaller sections or segments like product type, application, and geographical regions to optimize marketing strategies, advertising technique and global as well as regional sales efforts of Cell Therapy Instrument Market.

Product Type Segmentation Human Cells Animal Cells

Industry Segmentation Cell Processing Cell Preservation Distribution & Handling Process Monitoring & Quality Control

Channel (Direct Sales, Distributor) Segmentation

Region Segmentation:

Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in Cell Therapy Instrument Market. The regional analysis section of the report offers an extensive analysis of the Cell Therapy Instrument Market based on region. The Cell Therapy Instrument Market will showcase a steady CAGR in the forecast year.

Unravelling the geographical landscape of the Cell Therapy Instrument Market:

Americas (United States, Canada, Mexico, Brazil)

APAC (China, Japan, Korea, Southeast Asia, India, Australia)

Europe (Germany, France, UK, Italy, Russia, Spain)

Middle East & Africa (Egypt, South Africa, Israel, Turkey, GCC Countries)

Some of the Points cover in Cell Therapy Instrument Market Research Report are:

Chapter 1: Overview of Cell Therapy Instrument Market

Definition

Specifications

Classification

Applications

Regions

Chapter 2: Market Competition by Players/Suppliers

Manufacturing Cost Structure

Raw Material and Suppliers

Manufacturing Process

Industry Chain Structure

Chapter 3: Sales (Volume) and Revenue (Value) by Region

Sales

Revenue and market share

Chapter 4, 5 and 6: Cell Therapy Instrument Market by Type, Application & Players/Suppliers Profiles

Market Share by Type & Application

Growth Rate by Type & Application

Drivers and Opportunities

Company Basic Information

Continued

Note: Regional Breakdown & Sectional purchase Available We provide Pie chats Best Customize Reports As per Requirements.

For more information and discount on this report, ask your query at:https://www.reportocean.com/industry-verticals/sample-request?report_id=bis64080

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, and Asia.

Contact Us: +1 888 212 3539 (US) +91-9997112116 (Outside US) Contact Person: Tom Email:[emailprotected]

Link:
Cell Therapy Instrument Market IN COVID-19: IMPLICATIONS AND BUSINESS OPPORTUNITIES FOR GROWTH GLOBALLY - Owned

2027 Projections: Gene Therapy for CNS Disorders Market Report By Type, Application And Regional Outlook – Bulletin Line

DataIntelo, one of the worlds prominent market research firms has announced a novel report on Global Gene Therapy for CNS Disorders Market. The report contains vital insights on the market which will support the clients to make the right business decisions. This research will help both existing and new aspirants for Gene Therapy for CNS Disorders market to figure out and study the market needs, market size, and competition. The report incorporates data regarding the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities, and the threats faced by key players during the forecast period of 2020-2027.

Get A Free Sample Report @ https://dataintelo.com/request-sample/?reportId=113131

Impact of COVID-19 on Gene Therapy for CNS Disorders Market

The report also includes the impact of ongoing global crisis i.e. COVID-19 on the Gene Therapy for CNS Disorders market and what the future holds for it. It provides an analysis of the effects of the pandemic on the global economy. The outbreak has directly disturbed the demand and supply chain. The report also analyzes the financial impact on firms and financial markets. DataIntelo has gathered insights from several delegates of the industry and got involved in the primary and secondary research to provide the clients with data and strategies to combat the market challenges during and after COVID-19 pandemic.

Benefits of buying the report:

Industry experts and research analysts have worked extensively to prepare the research report which will help you to give that extra edge in the competitive market. The market research report can be customized according to you to your needs. This means that DataIntelo can cover a particular product, application, or can provide a detailed analysis in the report. You can also purchase a separate report for a specific region.

You can buy the complete report @ https://dataintelo.com/checkout/?reportId=113131

Some of the major companies that are covered in this report:

Gilead (Kite Pharma) Amgen (BioVex) Novartis Roche (Spark Therapeutics) Bluebird Bio

*Note: Additional companies can be included on request

The market scenario is likely to be fairly competitive. To analyze any market with simplicity the market is fragmented into the following segments:

By Application:

Hospitals Clinics Others

By Type:

Ex Vivo In Vivo

By Geographical Regions

Asia Pacific: China, Japan, India, and Rest of Asia Pacific Europe: Germany, the UK, France, and Rest of Europe North America: The US, Mexico, and Canada Latin America: Brazil and Rest of Latin America Middle East & Africa: GCC Countries and Rest of Middle East & Africa

Segmenting the market into smaller components helps in analyzing the dynamics of the market with more clarity. Another key component that is included in the report is the regional analysis to assess the global presence of the Gene Therapy for CNS Disorders market. You can also opt for a yearly subscription of all the updates on the Gene Therapy for CNS Disorders market.

Request a sample before buying this report @ https://dataintelo.com/request-sample/?reportId=113131

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Gene Therapy for CNS Disorders Market Overview

Gene Therapy for CNS Disorders Supply Chain Analysis

Gene Therapy for CNS Disorders Pricing Analysis

Global Gene Therapy for CNS Disorders Market Analysis and Forecast by Type

Global Gene Therapy for CNS Disorders Market Analysis and Forecast by Application

Global Gene Therapy for CNS Disorders Market Analysis and Forecast by Sales Channel

Global Gene Therapy for CNS Disorders Market Analysis and Forecast by Region

North America Gene Therapy for CNS Disorders Market Analysis and Forecast

Latin America Gene Therapy for CNS Disorders Market Analysis and Forecast

Europe Gene Therapy for CNS Disorders Market Analysis and Forecast

Asia Pacific Gene Therapy for CNS Disorders Market Analysis and Forecast

Asia Pacific Gene Therapy for CNS Disorders Market Size and Volume Forecast by Application

Middle East & Africa Gene Therapy for CNS Disorders Market Analysis and Forecast

Competition Landscape

If you have any questions on this report, feel free to reach us! @ https://dataintelo.com/enquiry-before-buying/?reportId=113131

About DataIntelo:

DataIntelo has a vast experience in making customized market research reports in various industry verticals. Our motto is to provide complete client satisfaction. We cover in-depth market analysis, which consists of stipulating lucrative business strategies, especially for the new entrants and the emerging players of the market. We make sure that each report goes through intensive primary, secondary research, interviews, and consumer surveys before final dispatch.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also provide ongoing training and knowledge sharing to keep our analysts tapped into industry best practices and loaded with information.

Contact Info: Name: Alex Mathews Address: 500 East E Street, Ontario, CA 91764, United States. Phone No: USA: +1 909 545 6473 Email: [emailprotected] Website: https://dataintelo.com

View original post here:
2027 Projections: Gene Therapy for CNS Disorders Market Report By Type, Application And Regional Outlook - Bulletin Line

A & # 39; s slam Angels in the first MLB game with a new additional entry rule – NewsDio

The first major league game with a runner on additional innings was decided with a bang rather than a tap.

Marcus Semien started the end of the tenth at second base under the unpopular new rule and scored on Matt Olson's grand slam, sending the Oakland Athletics over the Los Angeles Angels 7-3 on Friday night.

GIANT PITCHER SAM COONROD REFUSES TO KNEE DURING THE TIME OF BLACK LIVES BY FAITH: "I AM A CHRISTIAN"

Olson, whose alert pitch from first base nailed Angels free agent Shohei Ohtani to the top of the tenth, hooked up with one out. The Athletics gathered around the plate to greet him on opening night.

It is definitely interesting. There will be more excitement, "Olson said." I think it would be much harder to go to 17 or 18 inning games with a guy in second place. You would think that sometime someone will probably get hit.

Major League Baseball instituted the controversial extra inning runner rule for this season to prevent games from dragging on amid a compressed 60-game schedule that began after a months delay due to the virus outbreak.

Ohtani, who had put an end to the Angels ninth, was not ready for that: the broadcast showed the Japanese star on the bench wearing a jersey when the game was extra. Surprised, someone reminded him that he had to go to the second and quickly got organized.

Ohtani tried to advance Jared Walsh's initial landing, but was tagged in a summary.

TAMPA BAY LIGHTNING CALLS TO DETECT OFFICERS INVOLVED IN BREONNA TAYLOR'S DEATH OF SHOOTING

"I feel like we're going to see some different things with that," Olson said.

After Semien took second place, the Athletics loaded the bases against Hansel Robles (0-1) in a shot for a pitch, a wild pitch and a walk.

"Let's see what we do," former A-pitcher Dave Stewart wrote on Twitter, and then complained, "I suppose hitting is not an option?"

Then: "We don't need any stinky touches."

Angels new manager Joe Maddon brought in reliever Hoby Milner and, with a five-man inside box in place, Olson hit the first pitch well above the wall in right field.

According to STATS, Olson became the third player to reach a starting Grand Slam on opening day. He joined Sixto Lezcano (1980 Brewers) and Jim Presley (1986, Marineros).

Burch Smith (1-0) pitched an inning for victory.

The game went to the tenth tied at 3 after Jason Castro's home run in the ninth against A closer Liam Hendriks.

The Angels did not achieve a victory for Maddon in his debut as manager of the Angels. Maddon joined the Angels after five seasons guiding the Chicago Cubs.

CLICK HERE FOR MORE SPORTS COVERAGE AT FOXNEWS.COM

"We're basically playing a third of a season, so it's like losing a three-game series." That's what it feels like, "Angels starter Andrew Heaney said.

Many of the Angels, including Justin Upton and Brian Goodwin, knelt for the national anthem, while Athletics players Khris Davis and Tony Kemp raised their right fists to the air.

Los Angeles opened the season in Oakland for the fourth consecutive year.

TWO DECADES

At age 40, Albert Pujols had his 20th consecutive start on Opening Day in the same number of years the fifth player to start the opening in 20 consecutive years. The Others: Pete Rose, Carl Yastrzemski, Eddie Murray, and Frank Robinson.

It was 0 for 3 with a walk.

"Pretty spectacular, isn't it?" Maddon said. That puts everything in perspective of how great he is, how his career has looked, just to have 20 chances, you have to be good. We've had a lot of great conversations lately, me and him. Very happy for him and his family. I know it is important to him. He's definitely ready for rock and roll. "

COACH ROOM

Angeles: New 3B Anthony Rendon missed the first game with an oblique injury. "It has progressed, it encourages me," Maddon said.

Athletics: LHP A.J. Puk, on the disabled list with a tense shoulder, played catch. General manager David Forst said Puk would go to the club's alternate site in San Jose when the club hits the road. Puk received injections of platelet-rich plasma and cortisone on Monday. "It's going to be at least a couple of weeks just playing catch," manager Bob Melvin said. "We are a long way from having an update on him."

THAT FEAT

David Rinetti, A's vice president of stadium operations, marked his 40th inaugural day with the organization after first working in 1981 as a high school student. He received a 113-page document to prepare the stadium in two weeks.

"It's pretty incredible. It was a lot of work," said Rinetti.

UNTIL NEXT TIME

LHP Sean Manaea, who was 4-0 last season in September after returning from shoulder surgery before losing the wild card game, pitches Saturday against the Angels RHP Dylan Bundy.

Originally posted here:
A & # 39; s slam Angels in the first MLB game with a new additional entry rule - NewsDio

Why I Walk To End Alzheimer’s – TAPinto.net

The Alzheimer's Association Greater New Jersey Chapter is spotlighting people who make a difference in the fight to end Alzheimer's and all other dementia, by participating in the upcoming 2020 Walk To End Alzheimers (WTEA)the worlds largest event to raise awareness and funds for Alzheimers care, support and research. Today we say "thank you" toAnnie Butt.

Annie, a student at New Jersey Institute of Technology where she is studying biomedical engineering and stem cell research, is the Chair of the Essex-Hudson-Union Walk Committee. In addition to conducting outreach to local colleges and community-based organizations encouraging them to volunteer and participate in the Walk, she also creates promotional graphics used on the Chapters social media platforms designed to engage participants and show appreciation.

Joining the Walk to End Alzheimer's has been such an exciting opportunity for me! said Annie. As someone who has a passion for medicine, I want to participate in the Walk to End Alzheimer's, especially since there is no cure for the disease. I am constantly lookingforward to meeting new people through the Association and hearing the stories ofindividualswith loved ones affected by Alzheimer's and helping in any way that I can.

Sign Up for Livingston Newsletter

Our newsletter delivers the local news that you can trust.

You have successfully signed up for the TAPinto Livingston Newsletter.

More than 5 million Americans are living with Alzheimer's disease, the sixth-leading cause of death in the U.S. and the only disease among the top 10 causes that cannot be cured, prevented or even slowed. Additionally, more than 16 million family and friends provide care to people with Alzheimers and other dementias in the U.S. In New Jersey alone, there are more than 190,000 people living with the disease and 448,000 caregivers.

Register your team today. Sign up as a Team Captain or register to walk as an individual. Learn more at alz.org/njwalk. To donate, text 2ENDALZ to 51555, or contact us at gnjwalks@alz.org for more information.

Follow this link:
Why I Walk To End Alzheimer's - TAPinto.net

Personalized Cell Therapies Market Statistics, Facts and Figures, Growth Overview, Size, SWOT Analysis and Forecast to 2026 by PCT Cell Therapy…

The latest fundamental insights on Personalized Cell Therapies Market with COVID-19 Industry Impact, Forecast Development Scope, and Growth Prospects 2021-2026 is released by PBI. Every market driver, Personalized Cell Therapies marketing channel, growth-driving segments, risk analysis & mitigation is given in this report. The dynamic effects on worldwide Personalized Cell Therapies economies and crucial primary & secondary data sources offered in this study. The Personalized Cell Therapies Industry competitive landscape, regional analysis, future patterns, Top companies, current development rate, & gross margin status is provided.

The Personalized Cell Therapies Industry landscape view, demand, revenue, market share & pricing structure analysis is offered. The changing Industry dynamics, plans, CAGR, COVID-19 impact on consumer demand, availability of raw materials is analyzed completely. The market development rate during 2020-2025 with past & present industry performance is assessed in this report.

Get Sample Report Copy (Including TOC, portrayal, tables and graphs) Here: https://www.precisionbusinessinsights.com/request-sample?product_id=17290

The top companies & competitive landscape study is as follows:

PCT Cell Therapy Services, LLC (U.S),S. Stem Cell, Inc. (U.S),Bellicum Pharmaceuticals, Inc. (U.S),Saneron CCEL Therapeutics, Inc. (U.S),StemGenex (U.S),Vericel Corporation.(U.S)

By Cell Type

Market Analysis By Regions

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

South America (Brazil, Argentina, Columbia)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Request to customize @ https://www.precisionbusinessinsights.com/request-customisation?product_id=17290

Below is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

Personalized Cell Therapies Market Overview

Personalized Cell Therapies Supply Chain Analysis

Personalized Cell Therapies Pricing Analysis

Global Personalized Cell Therapies Market Analysis and Forecast by Type

Global Personalized Cell Therapies Market Analysis and Forecast by Application

Global Personalized Cell Therapies Market Analysis and Forecast by Sales Channel

Global Personalized Cell Therapies Market Analysis and Forecast by Region

North America Personalized Cell Therapies Market Analysis and Forecast

Latin America Personalized Cell Therapies Market Analysis and Forecast

Europe Personalized Cell Therapies Market Analysis and Forecast

Asia Pacific Personalized Cell Therapies Market Analysis and Forecast

Middle East & Africa Personalized Cell Therapies Market Analysis and Forecast

Competition Landscape

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights. We at Precision Business Insights are passionate about market research and love to do the things in an innovative way. Our team is a big asset for us and great differentiating factor. Our company motto is to address client requirements in the best possible way and want to be a part of our client success. We have a large pool of industry experts and consultants served a wide array of clients across different verticals. Relentless quest and continuous endeavor enable us to make new strides in market research and business consulting arena.

Contact Us:

[emailprotected]

PH +1-866-598-1553

Read the original post:
Personalized Cell Therapies Market Statistics, Facts and Figures, Growth Overview, Size, SWOT Analysis and Forecast to 2026 by PCT Cell Therapy...

Stem Cell Artificial Meat Market Analysis by Size, Share, Growth, Application, Segmentation and Forecast to 2027 – Bulletin Line

New Jersey, United States,- The research report on Fire Resistant Low Smoke Zero Halogen (LS0H) Cables market comprises of insights in terms of pivotal parameters such as production as well as the consumption patterns alongside revenue estimations for the projected timeframe. Speaking of production aspects, the study offers an in-depth analysis regarding the manufacturing processes along with the gross revenue amassed by the leading producers operating in this business arena. The unit cost deployed by these producers in various regions during the estimated timeframe is also mentioned in the report.

Significant information pertaining to the product volume and consumption value is enlisted in the document. Additionally, the report contains details regarding the consumption graphs, Individual sale prices, and import & export activities. Additional information concerning the production and consumption patterns are presented in the report.

In a word, the Fire Resistant Low Smoke Zero Halogen (LS0H) Cables Market report provides major statistics on the state of the Fire Resistant Low Smoke Zero Halogen (LS0H) Cables industry with a valuable source of guidance and direction for companies and individuals interested in the market. In the end, Fire Resistant Low Smoke Zero Halogen (LS0H) Cables Market report delivers a conclusion which includes Research Findings, Market Size Evaluation, Global Market Share, Consumer Needs along with Customer Preference Change, Data Source. These factors will raise the growth of the business overall.

Regions Covered in the Global Fire Resistant Low Smoke Zero Halogen (LS0H) Cables Market:

The Middle East and Africa (GCC Countries and Egypt)

North America (the United States, Mexico, and Canada)

South America (Brazil etc.)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report:

Accurate market size and CAGR forecasts for the period 2020-2026

Identification and in-depth assessment of growth opportunities in key segments and regions

Detailed company profiling of top players of the global Fire Resistant Low Smoke Zero Halogen (LS0H) Cables market

Exhaustive research on innovation and other trends of the global Fire Resistant Low Smoke Zero Halogen (LS0H) Cables market

Reliable industry value chain and supply chain analysis

Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report offers a complete company profiling of leading players competing in the global Fire Resistant Low Smoke Zero Halogen (LS0H) Cables marketwith a high focus on the share, gross margin, net profit, sales, product portfolio, new applications, recent developments, and several other factors. It also throws light on the vendor landscape to help players become aware of future competitive changes in the global Fire Resistant Low Smoke Zero Halogen (LS0H) Cables market.

Reasons to Buy the Report:

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Read more from the original source:
Stem Cell Artificial Meat Market Analysis by Size, Share, Growth, Application, Segmentation and Forecast to 2027 - Bulletin Line

Sickle cell anemia: Could gene therapy cure sickle cell anemia? "60 Minutes" – CBS News

Twenty years ago, scientists stunned the world when they announced they had decoded the genes that make up a human being. They hoped to use that genetic blueprint to advance something called gene therapy which locates and fixes the genes responsible for different diseases.

As we first reported last year, a clinical trial at the National Institutes of Health is doing exactly that in an attempt to cure sickle cell anemia a devastating genetic disease that kills hundreds of thousands of people around the world every year.

For 15 months we followed the scientists, and patients, who are ushering in a genetic revolution.

Jennelle Stephenson: I'm excited.

Ray Stephenson Today is the big day.

It's the day after Christmas, 2017, and 27-year-old Jennelle Stephenson has come with her father and brother from Florida to the National Institutes of Health, just outside Washington, D.C.

Jennelle Stephenson: Good morning.

Dr. John Tisdale: Good morning.

She's one of a small group of patients to receive an infusion containing altered DNA.

Nurse: This is what they look like.

Jennelle Stephenson: Merry Christmas to me.

Brother: Best Christmas present ever.

Jennelle Stephenson: Yay.

The clear liquid in the bag contains Jennelle's stem cells that have been genetically modified.

Dr. John Tisdale: There are about 500 million in there.

Jennelle Stephenson: Oh, my goodness.

The hope is the new DNA in the cells will cure Jennelle of sickle cell anemia, a brutal disease that causes debilitating pain.

Dr. Jon LaPook: At its worst, on a scale of zero to 10, how bad was your pain?

Jennelle Stephenson: We can go beyond a 10. It's terrible, it's horrible.

Dr. Jon LaPook: Pain where?

Jennelle Stephenson: Everywhere. My back, my shoulders, elbows, arms, legs, even my cheekbones, just pain.

Dr. Jon LaPook: Can you actually describe it?

Jennelle Stephenson: It's a very sharp, like, stabbing, almost feels like bone-crushing pain. Feels like someone's kind of constricting your bones, and then releasing constantly.

Pain from sickle cell can occur anywhere blood circulates. That's because red blood cells, normally donut-shaped, bend into an inflexible sickle shape, causing them to pile up inside blood vessels. The resulting traffic jam prevents the normal delivery of oxygen throughout the body, leading to problems that include bone deterioration, strokes and organ failure.

The gene that causes sickle cell anemia evolved in places like sub-Saharan Africa because it protects people from malaria. There, millions have the disease, and it's estimated more than 50 percent of babies born with it die before the age of five.

In the United States, it affects a hundred thousand people, mostly African-Americans.

For Jennelle, having the disease as a child often meant spending Christmas in the hospital. As an adult, she struggled through pain to complete college, but keeping a job was tough because something as simple as walking up stairs could trigger "a pain crisis."

Dr. Jon LaPook: Do you have friends who've died from sickle cell?

Jennelle Stephenson: I do. Yes, younger than me.

Dr. Jon LaPook: And you've known this your whole life growing up?

Jennelle Stephenson: Right.

Dr. Jon LaPook: That you could potentially die early?

Jennelle Stephenson: Right. Yes.

Dr. Jon LaPook: Did you think you would die early?

Jennelle Stephenson: I did, actually. When I hit about 22, I was like, "You know, I'm-- for a sickle celler, I'm kind of middle-aged right now."

Dr. Jon LaPook: What are some of the things that you've always wanted to do that you couldn't do?

Jennelle Stephenson: Honestly, everybody laughs at me for this, I just want to run, to be honest.

Dr. Jon LaPook: Things that most people would take for granted.

Jennelle Stephenson: Just basic things.

One of the most cruel parts of the disease, Jennelle and other patients have told us, is being accused of faking pain to get narcotics, being labeled a "drug-seeker." During one trip to the emergency department, when she fell to the floor in pain, a doctor refused to help her.

Jennelle Stephenson: And I'm looking up at her, and I'm in tears, and, I'm like, "I'm doing the best that I can."

Dr. Jon LaPook: And you gotta be thinking.

Jennelle Stephenson: I just, sometimes I don't understand, I don't get it. Like... Sorry. I'm in so much pain, and you think I just want some morphine. And it just makes me sad that some people in the medical community just don't get it.

Dr. Francis Collins is director of the National Institutes of Health, the largest biomedical research agency in the world. He oversees a nearly 40 billion dollar budget that funds more than 400,000 researchers world-wide.

Dr. Collins was head of the Human Genome Project at the NIH in 2000 when he made a landmark announcement: after a decade of work, scientists had finally decoded the genes that make up a human being.

Dr. Jon LaPook: When did it all start for you?

Dr. Francis Collins: I got excited about genetics as a first-year medical student. A pediatric geneticist came to teach us about how genetics was relevant to medicine. And he brought patients to class and one of the first patients he brought was a young man with sickle cell disease who talked about the experience of sickle cell crises and how incredibly painful those are. And yet, it was all because of one single letter in the DNA that is misplaced, a "T" that should have been an "A." And that was profound. You could have all of that happen because of one letter that was misspelled.

The double helix of DNA is made up of billions of pieces of genetic information. What Dr. Collins is saying is, out of all that, it's just one error in the DNA code -- a "T" that should have been an "A" -- that causes sickle cell anemia. Fix that error, and you cure the disease.

But figuring out how to do that would take more than 20 years of research and a little serendipity.

Dr. Collins was playing in the NIH rock band in 2016 when his bass player -- hematologist Dr. John Tisdale -- started riffing on an idea.

Dr. John Tisdale: We'd finished setting up and went for a pizza before--

Dr. Francis Collins: I remember that.

Dr. John Tisdale: --before the gig. And at this point I pitched to Francis that it was really time that we do something definitive for sickle cell disease.

In the laboratory, Dr. Tisdale and his collaborators created a gene with the correct spelling. Then, to get that gene into the patient, they used something with a frightening reputation: HIV, the virus that causes AIDS. It turns out HIV is especially good at transferring DNA into cells.

Here's how it works. The corrected gene, seen here in yellow, is inserted into the HIV virus. Then, bone marrow stem cells are taken from of a patient with sickle cell anemia. In the laboratory those cells are combined with the virus carrying that new DNA.

Dr. John Tisdale: This virus will then find its way to one of those cells and drop off a copy or two of the correctly spelled gene. And then these cells will go back to the patient.

If the process works, the stem cells with the correct DNA will start producing healthy red blood cells.

Dr. Jon LaPook: I can hear people, our viewers out there, thinking, "Wait a second, how do you know you're not gonna get AIDS from the HIV virus?"

Dr. John Tisdale: The short answer is we cut out the bits that cause infection in HIV and we really replace that with the gene that's misspelled in sickle cell disease so that it transfers that instead of the infectious part.

Dr. Jon LaPook: The stakes here are enormous.

Dr. Francis Collins: Yes.

Dr. Jon LaPook: There's really very little safety net here, right?

Dr. Francis Collins: Make no mistake, we're talking about very cutting-edge research where the certainty about all the outcomes is not entirely there. We can look back at the history of gene therapy and see there have been some tragedies.

Dr. Jon LaPook: Deaths?

Dr. Francis Collins: Yes.

In 1999, 18-year-old Jesse Gelsinger received altered DNA to treat a different genetic disease. He died four days later from a massive immune response. And in another trial, two children developed cancer.

Jennelle Stephenson understands. This is a trial with huge risks and no guarantees.

Jennelle Stephenson: This is it.

When she arrived at the NIH clinical center in December 2017, Jennelle asked her brother, Ray, for some help.

Jennelle Stephenson: There goes Ray cutting my hair. Oh, snip.

She decided to cut off all her hair, rather than watch it fall out from the massive dose of chemotherapy needed to suppress her immune system so her body wouldn't reject the altered stem cells.

Jennelle Stephenson: I don't know how to feel right now. I'm a little emotional. But I'm OK, it will grow back.

A few days after the chemotherapy, Jennelle received the infusion of genetically modified cells.

Dr. John Tisdale: Is it going good now?

Nurse: Yes.

Jennelle Stephenson: It's just a waiting game.

But the wait was a painful one. Not only for Jennelle, but also for her father Ray. Who did what little he could as the effects of the chemotherapy kicked in, stripping Jennelle's throat and stomach of their protective layers.

Jennelle Stephenson: Oh, that hurts.

She was unable to speak for a week and lost 15 pounds. And because having a severely weakened immune system means even a mild cold can turn deadly, Jennelle had to stay in the hospital for nearly a month.

After moving back to Florida, she returned to the NIH for periodic check-ups.

Dr. John Tisdale: These are her red blood cells.

It didn't take long for Dr. Tisdale to notice something was happening.

Dr. Jon LaPook: This is Jennelle before any treatment?

Dr. John Tisdale: Right. All across her blood you can see these really abnormal shapes. This one in particular is shaped like a sickle.

Nine months later, this is what Dr. Tisdale saw: not a sickle cell in sight.

Dr. Jon LaPook: Was there ever a moment where you saw one of these normal-looking smears and thought, "Is this the right patient?"

Dr. John Tisdale: Oh, absolutely. When you're a scientist, you're skeptical all the time. So, first thing you do is look and make sure it's that patient, go grab another one, make sure it's the same. And we've done all that. And, indeed, her blood looks normal.

Jiu-Jitsu Teacher: Move. Switch your arms and move.

Remember, Jennelle used to struggle just to walk up a flight of stairs...

Jiu-Jitsu Teacher: And you fall.

...and a fall like this would have landed her in the hospital.

Jiu-Jitsu Teacher: Boom. Yeah. Good job. You did it. Bam.

Dr. Jon LaPook: Jennelle. You look amazing.

Jennelle Stephenson: Thank you.

Dr. Jon LaPook: I have to say, I was a little nervous when you were thrown and you went down on the mat.

Jennelle Stephenson: It was nothing. It was nothing. My body just felt strong.

Dr. Jon LaPook: Tell me about the adjustment that you need to make to go from the old you to the new you.

Jennelle Stephenson: My body it almost felt like it was, like, itching to do more. And I was like, "All right, well, let's go swimming today." "Let's go to the gym today." I'm like, all right, my body loves this. I kinda like it because my, I guess all my endorphins started pumping.

Dr. Jon LaPook: The endorphin high, something you had never experienced.

Jennelle Stephenson: Never experienced before. Yup.

View post:
Sickle cell anemia: Could gene therapy cure sickle cell anemia? "60 Minutes" - CBS News